KOPRAN
|
The Current P/E Ratio of KOPRAN is 41.58.
| Share Price | ₹151.5 | Jan 01,2026 |
| Market Cap | ₹731.7 Cr | |
| Earnings-TTM | ₹17.6 Cr | TTM-Consolidated Results |
| Price/Earnings | 41.58x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹731.7 Cr] as on Jan 01,2026
(/) Earnings [ ₹17.6 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 41.58x ]
Thus, for KOPRAN , the investors are currently willing to pay 41.58 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.11x.
- KOPRAN 's operated at median p/e ratio of 21.93x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2021 of 7.37x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| KOPRAN | 17.60 | 41.58 | 731.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 39.25 | 412,782.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 67.76 | 168,376.0 |
| CIPLA LTD | 5,453.86 | 22.22 | 121,174.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 60.85 | 130,225.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.29 | 104,629.0 |
| MANKIND PHARMA LTD | 1,767.06 | 50.53 | 89,293.9 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.50 | 92,020.1 |
| LUPIN LTD | 4,347.53 | 22.10 | 96,078.5 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.10 | 69,283.8 |
| ABBOTT INDIA LTD | 1,508.95 | 40.11 | 60,531.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.29x |
| Max industry PE | 67.76x |
| Median industry PE | 39.25x |
| Average industry PE | 36.48x |
You may also like the below Video Courses